Germany will launch an oral tablet version of the weight-loss medication Wegovy on Sept. 1 [3].
The introduction of a pill formulation marks a significant shift in obesity treatment by removing the requirement for injections. This change aims to increase patient compliance and expand access for those who are averse to needles.
The medication contains the active ingredient semaglutide. While Wegovy has previously been available as an injection, this tablet is the first oral semaglutide therapy of its kind in Europe [4]. The European Union granted official approval for the tablets in July [2].
Health officials are introducing the drug as Germany faces a widespread public health challenge. Current data indicates that over 50% of the German population is overweight [1]. The oral alternative is designed to provide a more convenient method for managing weight control within this demographic.
Patients who qualify for the treatment can now seek the tablet as a non-injectable option. The drug works by mimicking hormones that target appetite and digestion, though the oral delivery method differs from the subcutaneous injection process. The rollout follows the EU's regulatory clearance earlier this summer.
Medical providers in Germany expect the availability of the pill to simplify the administration of semaglutide. By offering a tablet, the healthcare system can potentially reach a broader range of patients who struggle with the logistics or discomfort of injectable therapies.
“The European Union granted official approval for the tablets in July.”
The transition from injectable to oral semaglutide represents a strategic effort to scale obesity treatment. By lowering the barrier to entry—specifically the psychological and physical hurdle of injections—health providers can treat a larger segment of the overweight population more efficiently. This shift may increase the overall adoption of GLP-1 receptor agonists across the European Union.
